Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland. Show more
20400 Century Boulevard, Germantown, MD, 20874, United States
Market Cap
22.06M
52 Wk Range
$0.51 - $2.92
Previous Close
$0.54
Open
$0.57
Volume
19,133
Day Range
$0.54 - $0.62
Enterprise Value
-37.11M
Cash
70.46M
Avg Qtr Burn
-4.242M
Insider Ownership
13.37%
Institutional Own.
40.88%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
VTP-300 +/- Nivolumab Details Chronic hepatitis B | Phase 2b Update | |
VTP-300 (Viral Vector Vaccine) Details Chronic Hepatitis B | Phase 2 Update | |
VTP-300 (Viral Vector Vaccine) Details Chronic Hepatitis B | Phase 2 Update | |
VTP-300 (Therapeutic Vaccine) Details Chronic Hepatitis B | Phase 2 Update | |
VTP-300 (Therapeutic HBV Vaccine) Details Chronic Hepatitis B | Phase 2 Update | |
VTP-300 (Immune Modulator) Details Chronic Hepatitis B | Phase 2 Update | |
VTP-300 + AB-729 Details Chronic hepatitis B | Phase 2a Update | |
VTP-600 (Immune Modulator) Details Non-Small Cell Lung Cancer | Phase 1/2 Data readout | |
VTP-600 Details Non-small cell lung carcinoma | Phase 1/2 Data readout | |
VTP-600 (Viral Vector Vaccine) Details Non-Small Cell Lung Cancer | Phase 1/2 Data readout | |
VTP-600 (Cancer Vaccine) Details Non-Small Cell Lung Cancer | Phase 1/2 Update | |
VTP-200 Details Human papillomavirus | Phase 1/2 Update | |
VTP-600 (Cancer Vaccine) Details Non-Small Cell Lung Cancer | Phase 1/2 Update | |
VTP-1000 Details Celiac disease | Phase 1 Data readout | |
VTP-850 Details Prostate cancer | Phase 1 Update |
